The α7 nicotinic acetylcholine receptor positive allosteric modulator prevents lipopolysaccharide-induced allodynia, hyperalgesia and TNF-α in the hippocampus in mice
Authors:
- 3 July 2019
- journal article
- research article
- Published by Springer Nature in Pharmacological Reports
- Vol. 71 (6) , 1168-1176
Abstract
Background: Previous studies have shown that α7 nicotinic acetylcholine receptor (nAChR) has a critical role in the regulation of pain sensitivity and neuroinflammation. However, pharmacological effects of α7 nAChR activation in the hippocampus on neuroinflammatory mechanisms associated with allodynia and hyperalgesia remain unknown. We have determined the effects of 3a,4,5,9b-tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS), an α7 nAChR positive allosteric modulator, on lipopolysaccharide (LPS)-induced allodynia and hyperalgesia in mice. We also evaluated the effects of TQS on immunoreactivity of microglial marker ionized-calcium binding adaptor molecule 1 (Iba-1), phospho-nuclear factor-κB (p-NF-κB p65), tumor necrosis factor-alpha (TNF-α), and norepinephrine (NE) level. Methods: Mice were treated with (0.25, 1 or 4 mg/kg, ip) followed by LPS (1 mg/kg, ip) administration. Allodynia and hyperalgesia were determined using von Frey filaments and hot plate respectively. Immunoreactivity of Iba-1, p-NF-κB p65, and TNF-α, were measured in the hippocampus using immunofluorescence assay. Hippocampal NE level was evaluated using high performance liquid chromatography. Results: LPS administration resulted in allodynia and hyperalgesia in mice after six h. Systemic administration of TQS prevented LPS-induced allodynia and hyperalgesia. TQS pretreatment significantly decreased the immunoreactivity of Iba-1, p-NF-κB, and TNF-α in CA1 and DG regions of the hippocampus. In addition, TQS reversed LPS-induced NE reduction in the hippocampus. Conclusions: Taken together, our results suggest that TQS prevented LPS-induced allodynia and hyperalgesia, upregulation of TNF-α expression and NE level reduction involving microglial α7 nAChR in part in the hippocampus. Therefore, these findings highlight the important effects of α7 nAChR allosteric modulator against symptoms of inflammatory pain.Keywords
Funding Information
- Fulbright Foundation, USA and SDSU Research Foundation
- NIH (GM 57481)
This publication has 46 references indexed in Scilit:
- The α7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU‐120596 both alleviate inflammatory hyperalgesia and cytokine release in the ratBritish Journal of Pharmacology, 2012
- Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitationsBiochemical Pharmacology, 2011
- Antinociceptive and anti-inflammatory effects of choline in a mouse model of postoperative painBritish Journal of Anaesthesia, 2010
- Hippocampal correlates of pain in healthy elderly adultsNeurology, 2009
- Activation and Desensitization of Nicotinic α7-type Acetylcholine Receptors by Benzylidene Anabaseines and NicotineThe Journal of Pharmacology and Experimental Therapeutics, 2009
- The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammationBritish Journal of Pharmacology, 2007
- Neuronal Mechanism for Neuropathic PainMolecular Pain, 2007
- Chronic Neuropathic PainThe Neurologist, 2005
- The functional anatomy of neuropathic painNeurosurgery Clinics of North America, 2004
- Descending control of painProgress in Neurobiology, 2002